PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

New Health Capital Partners closes investment fund with anchor investment from ORIX USA Asset Management

New Health Capital Partners has closed on New Health Capital Partners Fund I LP, a private equity vehicle focused on investing throughout the capital structure of life sciences companies, including senior secured loans, royalty monetizations, control equity investments and other structured financings.

The New York-based firm received an initial capital commitment of USD150,000,000 from ORIX USA Asset Management (OAM), a global asset management firm.

NHCP seeks to create highly customised investment structures which provide significantly more flexibility to companies than capital traditionally available via the public markets, private equity or pure royalty monetization firms. New Health is uniquely able to provide capital to a broad spectrum of commercial-stage specialty pharmaceutical, medical devices, diagnostics and technology tools companies.
The founders of NHCP, Richard Baxter and Aron Dantzig, have worked together for the past seven years, deploying in excess of USD1 billion. NHCP’s principals have completed one transaction since the firm’s launch and are reviewing a number of additional investment opportunities as the firm rapidly broadens its transaction pipeline.

"We are excited to announce our launch with the substantial capital commitment from ORIX USA Asset Management," says Richard Baxter, "and look forward to continuing to deploy innovative forms of capital into the healthcare industry."
Michael Blum, President and CEO of ORIX USA Asset Management, commented, "We are very excited about our relationship with NHCP. Partnering with Aron and Rich and their team gives ORIX USA Asset Management a unique opportunity to invest in the healthcare and life sciences sectors and further highlights our commitment to the global asset management industry."

"Access to cost-efficient capital continues be a challenge for many life science-focused companies," adds Aron Dantzig. "And we are seeing consistently increasing demand for our type of non-traditional capital."

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured